Sol-Gel Technologies Number of Employees 2016-2024 | SLGL

Sol-Gel Technologies number of employees from 2016 to 2024. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Sol-Gel Technologies Annual Employee Count
2024 N/A
2023 36
2022 55
2021 53
2020 65
2019 61
2018 56
2017 49
2016 47
2015 N/A
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.021B $0.012B
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $17.586B 6.44
Dr Reddy's Laboratories (RDY) India $11.620B 22.17
BridgeBio Pharma (BBIO) United States $7.284B 0.00
Bausch Health Cos (BHC) Canada $1.958B 1.41
Supernus Pharmaceuticals (SUPN) United States $1.813B 16.92
Amphastar Pharmaceuticals (AMPH) United States $1.160B 7.01
Taysha Gene Therapies (TSHA) United States $0.398B 0.00
Personalis (PSNL) United States $0.334B 0.00
Assembly Biosciences (ASMB) United States $0.087B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00